Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enhanced FDA Oversight Added To GAO’s “High Risk” List

This article was originally published in The Tan Sheet

Executive Summary

The Government Accountability Office has added enhanced oversight of devices, drugs and other medical products to its list of "high risk" priorities

You may also be interested in...



Hamburg/Sharfstein Appointments Do Not Signal Split Duties At FDA

FDA's top leadership team will not split duties along food and medical products, sources close to the selection process say

Hamburg/Sharfstein Appointments Do Not Signal Split Duties At FDA

FDA's top leadership team will not split duties along food and medical products, sources close to the selection process say

FDA Commissioner Announcement Complicated By Daschle, Peanut Butter

The withdrawal of Tom Daschle's nomination as Health and Human Services secretary may pose a hurdle to the Obama administration's impetus to name an FDA commissioner, but does not change the two names on the shortlist

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel